{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T04:09:02Z","timestamp":1774066142847,"version":"3.50.1"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,11,30]],"date-time":"2021-11-30T00:00:00Z","timestamp":1638230400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Microbiol."],"abstract":"<jats:p>Finafloxacin is a novel fluoroquinolone with optimal antibacterial activity in low pH environments, therefore offering a therapeutic advantage over some traditional antibiotics, in treating bacterial infections associated with acidic foci. <jats:italic>Coxiella burnetii<\/jats:italic>, the causative agent of Q fever, is a bacterium which resides and replicates in acidic intracellular parasitic vacuoles. The efficacy of finafloxacin was evaluated <jats:italic>in vivo<\/jats:italic> using the A\/J mouse model of inhalational Q fever and was compared to doxycycline, the standard treatment for this infection and ciprofloxacin, a comparator fluoroquinolone. Finafloxacin reduced the severity of the clinical signs of infection and weight loss associated with Q fever, but did not reduce the level of bacterial colonization in tissues compared to doxycycline or ciprofloxacin. However, histopathological analysis suggested that treatment with finafloxacin reduced tissue damage associated with <jats:italic>C. burnetii<\/jats:italic> infection. In addition, we report for the first time, the use of viable counts on axenic media to evaluate antibiotic efficacy <jats:italic>in vivo<\/jats:italic>.<\/jats:p>","DOI":"10.3389\/fmicb.2021.760698","type":"journal-article","created":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T20:09:15Z","timestamp":1638389355000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Finafloxacin, a Novel Fluoroquinolone, Reduces the Clinical Signs of Infection and Pathology in a Mouse Model of Q Fever"],"prefix":"10.3389","volume":"12","author":[{"given":"M. Gill","family":"Hartley","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isobel H.","family":"Norville","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark I.","family":"Richards","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kay B.","family":"Barnes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin R.","family":"Bewley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Vipond","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emma","family":"Rayner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Vente","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stuart J.","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah V.","family":"Harding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,11,30]]},"reference":[{"key":"B1","first-page":"1","article-title":"Diagnosis and management of Q fever\u2014united states, 2013: recommendations from CDC and the Q fever working group.","volume":"62","author":"Anderson","year":"2013","journal-title":"Morbidity Mortality Weekly Rep. Recommend. Rep."},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00082-17","article-title":"Demonstrating the protective efficacy of the novel fluoroquinolone finafloxacin against an inhalational exposure to burkholderia pseudomallei.","volume":"61","author":"Barnes","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2019.00904","article-title":"The fluoroquinolone finafloxacin Protects BALB\/c mice against an intranasal infection with Francisella tularensis strain SchuS4.","volume":"10","author":"Barnes","year":"","journal-title":"Front. Microbiol."},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01470-19","article-title":"Demonstration of the broad spectrum in vitro activity of finafloxacin against pathogens of biodefence interest.","volume":"63","author":"Barnes","year":"","journal-title":"Antimicrob Agents Chemother"},{"key":"B5","first-page":"98","article-title":"Studies on Q fever in man.","volume":"69","author":"Benenson","year":"1956","journal-title":"Trans. Assoc. Am. Phys."},{"key":"B6","first-page":"469","article-title":"Animal models of Q fever (Coxiella burnetii).","volume":"63","author":"Bewley","year":"2013","journal-title":"Comput. Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1254.e1251","DOI":"10.1016\/j.cmi.2019.07.028","article-title":"Influence of pH on the activity of finafloxacin against extracellular and intracellular Burkholderia thailandensis, Yersinia pseudotuberculosis and Francisella philomiragia and on its cellular pharmacokinetics in THP-1 monocytes.","volume":"26","author":"Chalhoub","year":"2020","journal-title":"Clin. Microbiol. Infect."},{"key":"B8","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1016\/j.ijantimicag.2017.08.006","article-title":"Use of axenic media to determine antibiotic efficacy against Coxiella burnetii.","volume":"51","author":"Clay","year":"2018","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B9","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/s1473-3099(03)00658-3","article-title":"Immunomodulatory effects of quinolones.","volume":"3","author":"Dalhoff","year":"2003","journal-title":"Lancet Infect. Dis."},{"key":"B10","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.micinf.2019.09.001","article-title":"Coxiella burnetii: international pathogen of mystery.","volume":"22","author":"Dragan","year":"2020","journal-title":"Microb. Infect."},{"key":"B11","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1128\/CMR.00045-16","article-title":"From Q fever to Coxiella burnetii infection: a paradigm change.","volume":"30","author":"Eldin","year":"2017","journal-title":"Clin. Microbiol. Rev."},{"key":"B12","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1128\/JCM.36.7.1823-1834.1998","article-title":"Diagnosis of Q fever.","volume":"36","author":"Fournier","year":"1998","journal-title":"J. Clin. Microbiol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1152\/ajplegacy.1947.150.1.70","article-title":"Measurement of the respiratory volumes of laboratory animals.","volume":"150","author":"Guyton","year":"1947","journal-title":"Am. J. Physiol."},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2019.01552","article-title":"Comparison of PCR and viable count as a method for enumeration of bacteria in an A\/J Mouse aerosol model of Q fever.","volume":"10","author":"Hartley","year":"2019","journal-title":"Front. Microbiol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1128\/AAC.01637-09","article-title":"Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.","volume":"54","author":"Higgins","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"B16","doi-asserted-by":"publisher","first-page":"323","DOI":"10.2165\/00044011-199510060-00002","article-title":"Enteric coating reduces upper gastrointestinal adverse reactions to doxycycline.","volume":"10","author":"J\u00e4rvinen","year":"1995","journal-title":"Clin. Drug Investig"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1128\/JCM.03221-13","article-title":"Chronic Q fever in the Netherlands 5 years after the start of the Q fever epidemic: results from the Dutch chronic Q fever database.","volume":"52","author":"Kampschreur","year":"2014","journal-title":"J. Clin. Microbiol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1586\/14787210.2013.840534","article-title":"Antimicrobial therapies for Q fever.","volume":"11","author":"Kersh","year":"2013","journal-title":"Expert Rev. Anti. Infect. Ther."},{"key":"B19","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.ijantimicag.2011.03.002","article-title":"Activity of finafloxacin, a novel fluoroquinolone with increased activity at acid pH, towards extracellular and intracellular Staphylococcus aureus, Listeria monocytogenes and Legionella pneumophila.","volume":"38","author":"Lemaire","year":"2011","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B20","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1093\/qjmed\/hcp077","article-title":"Q fever: persistence of antigenic non-viable cell residues of Coxiella burnetii in the host\u2013implications for post Q fever infection fatigue syndrome and other chronic sequelae.","volume":"102","author":"Marmion","year":"2009","journal-title":"QJM"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1093\/infdis\/166.5.1097","article-title":"Phagolysosomal alkalinization and the bactericidal effect of antibiotics: the Coxiella burnetii paradigm.","volume":"166","author":"Maurin","year":"1992","journal-title":"J. Infect. Dis."},{"key":"B22","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1128\/CMR.12.4.518","article-title":"Q fever.","volume":"12","author":"Maurin","year":"1999","journal-title":"Clin. Microbiol. Rev."},{"key":"B23","doi-asserted-by":"publisher","first-page":"2116","DOI":"10.1128\/iai.00108-16","article-title":"Mouse model of Coxiella burnetii aerosolization.","volume":"84","author":"Melenotte","year":"2016","journal-title":"Infect. Immun."},{"key":"B24","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/S1473-3099(10)70135-3","article-title":"Long-term outcome of Q fever endocarditis: a 26-year personal survey.","volume":"10","author":"Million","year":"2010","journal-title":"Lancet Infect. Dis."},{"key":"B25","doi-asserted-by":"publisher","first-page":"5510","DOI":"10.1128\/AAC.03443-14","article-title":"Efficacy of liposome-encapsulated ciprofloxacin in a murine model of Q fever.","volume":"58","author":"Norville","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"B26","doi-asserted-by":"publisher","first-page":"3720","DOI":"10.1128\/AEM.02826-10","article-title":"Isolation from animal tissue and genetic transformation of Coxiella burnetii are facilitated by an improved axenic growth medium.","volume":"77","author":"Omsland","year":"2011","journal-title":"Appl. Environ. Microbiol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"4430","DOI":"10.1073\/pnas.0812074106","article-title":"Host cell-free growth of the Q fever bacterium Coxiella burnetii.","volume":"106","author":"Omsland","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B28","doi-asserted-by":"publisher","first-page":"4386","DOI":"10.1128\/AAC.00832-10","article-title":"Human pharmacokinetics and safety profile of finafloxacin, a new fluoroquinolone antibiotic, in healthy volunteers","volume":"55","author":"Patel","year":"2011","journal-title":"Antimicrob Agents Chemother."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1017\/S0950268810002268","article-title":"The Q fever epidemic in the Netherlands: history, onset, response and reflection.","volume":"139","author":"Roest","year":"2011","journal-title":"Epidemiol. Infect."},{"key":"B30","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1196\/annals.1355.039","article-title":"Activity of telithromycin against thirteen new isolates of C. burnetii including three resistant to doxycycline.","volume":"1063","author":"Rolain","year":"2005","journal-title":"Ann. N.Y. Acad. Sci."},{"key":"B31","doi-asserted-by":"publisher","first-page":"584","DOI":"10.4269\/ajtmh.15-0245","article-title":"Safety, tolerability, and compliance with long-term antimalarial chemoprophylaxis in American soldiers in Afghanistan.","volume":"93","author":"Saunders","year":"2015","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"B32","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1111\/j.1476-5381.2009.00267.x","article-title":"To scale or not to scale: the principles of dose extrapolation","volume":"157","author":"Sharma","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-54556-6","article-title":"The effect of ph on antibiotic efficacy against Coxiella burnetii in axenic media.","volume":"9","author":"Smith","year":"2019","journal-title":"Sci. Rep."},{"key":"B34","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/0954-6111(93)90006-l","article-title":"A large Q fever outbreak in the West Midlands: clinical aspects.","volume":"87","author":"Smith","year":"1993","journal-title":"Res. Med."},{"key":"B35","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1159\/000238584","article-title":"Conditions affecting the results of susceptibility testing for the quinolone compounds.","volume":"34","author":"Smith","year":"1988","journal-title":"Chemotherapy"},{"key":"B36","doi-asserted-by":"publisher","first-page":"4394","DOI":"10.1128\/AAC.00833-10","article-title":"In vitro spectrum of activity of finafloxacin, a novel, pH-activated fluoroquinolone, under standard and acidic conditions.","volume":"55","author":"Stubbings","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"B37","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1196\/annals.1374.112","article-title":"Diagnosis of acute Q fever by PCR on sera during a recent outbreak in rural south Australia.","volume":"1078","author":"Turra","year":"2006","journal-title":"Ann. N.Y. Acad. Sci."},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-12-280","article-title":"Assessing the long-term health impact of Q-fever in the Netherlands: a prospective cohort study started in 2007 on the largest documented Q-fever outbreak to date.","volume":"12","author":"van Loenhout","year":"2012","journal-title":"BMC Infect. Dis."},{"key":"B39","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1016\/j.cmi.2018.11.023","article-title":"Chronic Q fever-related complications and mortality: data from a nationwide cohort.","volume":"25","author":"van Roeden","year":"2019","journal-title":"Clin. Microbiol. Infect."},{"key":"B40","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1111\/j.1462-5822.2007.00901.x","article-title":"Lounging in a lysosome: the intracellular lifestyle of Coxiella burnetii.","volume":"9","author":"Voth","year":"2007","journal-title":"Cell Microbiol."},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02317-17","article-title":"Explorative randomized phase II clinical study of the efficacy and safety of finafloxacin versus ciprofloxacin for treatment of complicated urinary tract infections.","volume":"62","author":"Wagenlehner","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"B42","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.epidem.2015.07.001","article-title":"Kinetics of antibody response to Coxiella burnetii infection (Q fever): estimation of the seroresponse onset from antibody levels.","volume":"13","author":"Wielders","year":"2015","journal-title":"Epidemics"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199008303230917","article-title":"Ciprofloxacin in a case of Q fever endocarditis.","volume":"323","author":"Yebra","year":"1990","journal-title":"N. Engl. J. Med."}],"container-title":["Frontiers in Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2021.760698\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T20:09:21Z","timestamp":1638389361000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2021.760698\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,30]]},"references-count":43,"alternative-id":["10.3389\/fmicb.2021.760698"],"URL":"https:\/\/doi.org\/10.3389\/fmicb.2021.760698","relation":{},"ISSN":["1664-302X"],"issn-type":[{"value":"1664-302X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,30]]},"article-number":"760698"}}